IPP Bureau
Pfizer announces Phase 3 clinical trial for vaccine against Respiratory Syncytial Virus (RSV)
By IPP Bureau - September 03, 2021
RSV is a common and pervasive cause of severe acute respiratory illness in older adults with no vaccine currently available
Covid-19 vaccine clinical trial for people with autoimmune disease
By IPP Bureau - September 03, 2021
Researchers at the Feinstein Institutes administer extra vaccine doses as part of the NIH funded study
Novartis signs world’s first agreement with NHS, UK
By IPP Bureau - September 03, 2021
The agreement follows positive NICE recommendation and commits to deliver Leqvio (inclisiran) access via a population health management approach identifying eligible patients across England
CII awards Excellence in Energy efficiency to Sai Life Sciences API unit
By IPP Bureau - September 03, 2021
The Bidar API manufacturing facility of Sai Life Sciences has been on a path of significant expansion with its production capacity growing from 200KL in 2017 to 450KL
Digital adoption in healthcare will see exponential growth: Wipro GE study
By IPP Bureau - September 03, 2021
Key trends indicate that AI-based solutions, cloud-based healthcare solutions and digital transformations will be the key in the years to come.
Phase 2 of Covaxin intranasal trials begin in Kanpur
By IPP Bureau - September 02, 2021
The vaccine is designed to neutralise the virus in the nostril itself and prevent it from penetrating deep down into the respiratory tract
Natco Pharma launch Nat-Lenalidomide in Canada
By IPP Bureau - September 02, 2021
Nat-Lenalidomide, a generic alternative to Revlimid, expands affordable treatment options for patients with multiple myeloma and patients with transfusion-dependent anaemia due to myelodysplastic syndromes (MDS)
Reddy-Lenalidomide launched in Canada
By IPP Bureau - September 02, 2021
Dr. Reddy's Laboratories Canada announces the launch of Reddy-Lenalidomide, one of the first generic medications of its kind for the Canadian market
Sun Pharma Industries announce sale of Kayaku
By IPP Bureau - September 02, 2021
The company has been sold to Shinshin Pharmaceuticals
Medtech player Healthium acquires CareNow
By IPP Bureau - September 02, 2021
This is the third acquisition by Healthium this year apart from AbGel business in India and VitalCare in the UK
Medtronic partners with Stasis to enhance patient monitoring in India
By IPP Bureau - September 02, 2021
The Stasis connected care monitoring system includes - a bedside monitor that monitors 6 vital signs, a tablet that enables intuitive monitoring, and the Stasis app that allows for remote monitoring across devices
Janssen announces U.S. FDA approval of Invega Hafyera
By IPP Bureau - September 02, 2021
Invega Hafyera offers patients the fewest doses per year. Phase 3 non-inferiority study results showed over 92% of participants were relapse-free at 12 months
Granules India receive DRDO licence to manufacture and market 2-DG
By IPP Bureau - September 02, 2021
The drug has been granted permission by DCGI for emergency use as an adjunct therapy for Covid-19
Morpen Laboratories to transfer its medical devices business to a wholly owned subsidiary
By IPP Bureau - September 02, 2021
The revenues and profits derived from the new subsidiary will be consolidated in the parent company
Union Minister Mansukh Mandaviya chairs meet on eradicating TB
By IPP Bureau - September 02, 2021
Coordinated and collaborative efforts will strongly contribute to the achievement of shared goals faster: Mandaviya
